Haptoglobin 2 allele associates with unstable carotid plaque and major cardiovascular events
…, M Kähönen, YA Kesäniemi, PT Kovanen, M Kaste… - Atherosclerosis, 2013 - Elsevier
Objective Intraplaque hemorrhages (IPH) may predispose to unstable atherosclerotic disease
and its atherothrombotic complications, ischemic stroke and coronary syndromes. However…
and its atherothrombotic complications, ischemic stroke and coronary syndromes. However…
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
W Hacke, M Kaste, C Fieschi, R Von Kummer… - The Lancet, 1998 - thelancet.com
Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Background Early administration of intravenous recombinant tissue plasminogen activator (rt-PA)
after ischaemic stroke improves outcome. Previous analysis of combined data from …
after ischaemic stroke improves outcome. Previous analysis of combined data from …
[HTML][HTML] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
W Hacke, M Kaste, E Bluhmki, M Brozman… - New England journal …, 2008 - Mass Medical Soc
Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS)
Objective. —To evaluate the efficacy and safety of intravenous thrombolysis using recombinant
tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke. Design. —…
tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke. Design. —…
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
Background The aim of the Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) was to assess the safety and efficacy of intravenous alteplase as thrombolytic …
(SITS-MOST) was to assess the safety and efficacy of intravenous alteplase as thrombolytic …
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double …
…, LM Brass, C Cimminiello, L Csiba, M Kaste… - The Lancet, 2004 - thelancet.com
Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk …
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk …
[HTML][HTML] Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of …
Background Alteplase is effective for treatment of acute ischaemic stroke but debate continues
about its use after longer times since stroke onset, in older patients, and among patients …
about its use after longer times since stroke onset, in older patients, and among patients …
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase
…, A Davalos, M Eliasziw, M Fischer, A Furlan, M Kaste… - Stroke, 2005 - Am Heart Assoc
Background and Purpose— Most acute ischemic stroke patients arrive after the 3-hour time
window for recombinant tissue plasminogen activator (rtPA) administration. The …
window for recombinant tissue plasminogen activator (rtPA) administration. The …
[HTML][HTML] Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
…, V Gu, K Hermansson, L Hilbrich, M Kaste… - … England Journal of …, 2008 - Mass Medical Soc
Background Recurrent stroke is a frequent, disabling event after ischemic stroke. This study
compared the efficacy and safety of two antiplatelet regimens — aspirin plus extended-…
compared the efficacy and safety of two antiplatelet regimens — aspirin plus extended-…